Ovarian carcinoma

Reading File

What would you like to know about ovarian carcinoma?

Overview and types
Symptoms and diagnosis
Staging
Treatment
Prognosis
Exam-style notes

Explain ovarian carcinoma types, symptoms, and risk factors

Reading File

Searching the Web

ovarian cancer symptoms risk factors types American Cancer Society

Searching PubMed

ovarian cancer risk factors

Finding Sources

Reading File

Reading Web Page

https://www.cancer.org/cancer/types/ovarian-cancer/causes-ri…

Ovarian carcinoma: main types

Strictly, ovarian carcinoma refers to malignant epithelial tumors. In common usage, “ovarian cancer” also includes less common germ-cell and sex-cord stromal malignancies.

1. Epithelial ovarian carcinomas

These account for about 90% of malignant ovarian tumors and commonly arise from the ovary, fallopian tube, or peritoneum.

High-grade serous carcinoma (HGSC): the commonest and most aggressive type. It often starts in the fimbrial end of the fallopian tube and is strongly associated with TP53 alterations and, in a subset, inherited BRCA1/BRCA2 mutations.
Low-grade serous carcinoma: less common, slower growing, often associated with borderline serous tumors.
Endometrioid carcinoma: may be linked with endometriosis and can coexist with endometrial carcinoma.
Clear-cell carcinoma: also associated with endometriosis; may present at an earlier stage but can behave aggressively when advanced.
Mucinous carcinoma: large, mucin-producing tumors. A mucinous ovarian tumor should also prompt consideration of metastasis from the gastrointestinal tract.
Carcinosarcoma: rare, high-grade tumor containing both epithelial and mesenchymal malignant components.

2. Germ-cell tumors

These arise from ovarian germ cells and are more frequent in children, adolescents, and younger adults. Examples include dysgerminoma, yolk-sac tumor, and immature teratoma.

3. Sex-cord stromal tumors

These arise from ovarian supporting/hormone-producing cells. Examples include granulosa-cell and Sertoli-Leydig cell tumors. They may produce estrogen or androgens, producing endocrine symptoms such as abnormal uterine bleeding or virilization.

Symptoms

Early disease can cause no symptoms or only vague symptoms. When symptoms occur, they are often persistent rather than isolated:

Abdominal bloating or increasing abdominal size
Pelvic or lower abdominal pain, pressure, or discomfort
Feeling full quickly or difficulty eating
Urinary urgency or frequency
Altered bowel habit, including constipation
Fatigue, indigestion, back pain, or unintentional weight loss
Menstrual irregularity, especially in premenopausal people
Pain during intercourse

Advanced disease can cause ascites with marked abdominal distension, breathlessness from pleural effusion, bowel obstruction, and weight loss. Berek notes that symptoms are commonly vague and may result from mass effect, ascites, omental disease, or bowel involvement. Berek & Novak's Gynecology, p. 2327.

These symptoms are common and usually have non-cancer causes. However, bloating, pelvic/abdominal pain, early satiety, or urinary symptoms that occur frequently and persist for more than a few weeks should be assessed promptly, as advised by the American Cancer Society symptom guidance.

Risk factors

Most established risk factors relate primarily to epithelial ovarian carcinoma.

Non-modifiable or inherited factors

Increasing age, particularly after menopause
Family history of ovarian, breast, pancreatic, colorectal, or endometrial cancer
Inherited pathogenic variants, especially BRCA1 and BRCA2
Lynch syndrome and, less commonly, other hereditary cancer syndromes
Personal history of breast cancer
Endometriosis, particularly in relation to endometrioid and clear-cell carcinomas

Reproductive and hormonal factors

Factors associated with a greater lifetime number of ovulations have been associated with increased risk:

Early menarche
Late menopause
Nulliparity or infertility
First full-term pregnancy at a later age
Postmenopausal estrogen-only hormone therapy

Other associations

Overweight/obesity
Smoking, particularly associated with mucinous ovarian tumors
Prior pelvic radiation, in selected contexts

The American Cancer Society risk-factor summary emphasizes that a risk factor raises probability but does not mean a person will develop cancer. Conversely, ovarian cancer can occur without an identifiable risk factor.

Factors associated with lower risk

Combined oral contraceptive use
Pregnancy and breastfeeding
Tubal ligation or salpingectomy

Textbook pathology also reports reduced ovarian-cancer risk among people using oral contraceptives or who have had tubal ligation. Robbins, Cotran & Kumar Pathologic Basis of Disease, Pathogenesis section.

For someone with a strong family history of breast, ovarian, pancreatic, colorectal, or endometrial cancer, referral for genetic counseling and testing may be appropriate.

Breast cancer

Reading File

Which aspect of breast cancer would you like explained?

Types and subtypes
Symptoms and warning signs
Risk factors and prevention
Diagnosis and staging
Treatment
Complete exam-style overview

Explain breast cancer types and molecular subtypes

Reading File

Finding Sources

Searching PubMed

breast cancer molecular subtypes

Searching the Web

NCI breast cancer molecular subtypes luminal HER2 triple negative

Reading File

Finding Sources

Breast cancer types

Breast cancers are classified in two complementary ways:

Histologic type: what the tumor looks like under the microscope
Molecular subtype: its receptor and gene-expression profile, which guides treatment and prognosis

A. Non-invasive breast lesions

Ductal carcinoma in situ (DCIS): malignant epithelial cells are confined within breast ducts and have not invaded surrounding tissue. It is a non-invasive precursor lesion, not metastatic cancer.
Lobular carcinoma in situ (LCIS): abnormal cells fill lobules. Classic LCIS is mainly a marker of increased future breast-cancer risk in either breast, rather than an obligate direct precursor.

B. Invasive breast carcinomas

These have crossed the duct or lobule basement membrane and can spread to lymph nodes or distant organs.

Invasive carcinoma of no special type (NST): formerly called invasive ductal carcinoma. It is the commonest invasive histologic type, accounting for about 75% of invasive breast cancers. Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 565.
Invasive lobular carcinoma (ILC): the second most common type. Cells often infiltrate in single-file patterns because of loss of cell adhesion, commonly involving loss of E-cadherin expression. It may be multifocal or bilateral more often than NST.
Special histologic types: include tubular, mucinous, cribriform, papillary, metaplastic, and apocrine carcinoma. Some, such as tubular and mucinous carcinomas, often have a relatively favorable prognosis. Metaplastic carcinoma is usually higher grade and often triple-negative.
Inflammatory breast cancer: a clinical-pathologic presentation, not a separate histologic type. Tumor emboli obstruct dermal lymphatic vessels, causing rapid breast enlargement, erythema, edema, and peau d’orange. It is locally advanced at presentation.

Molecular subtypes

Molecular subtypes were first defined through gene-expression profiling. In everyday clinical practice, they are approximated by immunohistochemistry for:

Estrogen receptor (ER)
Progesterone receptor (PR)
HER2 expression/amplification
Ki-67 proliferation index, plus tumor grade in some classifications

Determining ER, PR, and HER2 status is essential before treatment planning. Current Surgical Therapy, 14th ed., p. 812.

Subtype	Typical receptor profile	General features	Main systemic treatment approach
Luminal A	ER-positive, usually PR-positive, HER2-negative; low Ki-67/low grade	Most common subtype; slower-growing and usually best prognosis	Endocrine therapy is central; chemotherapy is selective
Luminal B, HER2-negative	ER-positive; HER2-negative; higher Ki-67 and/or lower PR, higher grade	More proliferative and generally more aggressive than luminal A	Endocrine therapy; chemotherapy is more often considered
Luminal B, HER2-positive	ER-positive and/or PR-positive, HER2-positive	Hormone-responsive but HER2-driven biology is present	Endocrine therapy plus anti-HER2 treatment, often with chemotherapy
HER2-enriched / HER2-positive	HER2-positive; often ER-negative and PR-negative, though not always	Historically aggressive, but outcomes have improved markedly with HER2-targeted drugs	Anti-HER2 therapy, commonly with chemotherapy; endocrine therapy if hormone-receptor positive
Basal-like	Gene-expression subtype; often ER-negative, PR-negative, HER2-negative	Typically high grade, high proliferation, and frequently associated with BRCA1-related biology	Usually treated along triple-negative pathways
Triple-negative breast cancer (TNBC)	ER-negative, PR-negative, HER2-negative	Clinical immunohistochemical category, not identical to basal-like; frequently high grade and more likely to recur early	Chemotherapy; selected cases may receive immunotherapy, PARP inhibition for germline BRCA-associated disease, or antibody-drug conjugates
Claudin-low / normal-like	Gene-expression subgroups, less commonly used in routine care	Claudin-low tumors often show epithelial-mesenchymal and immune-related features; normal-like may partly reflect normal tissue contamination	Not usually a routine treatment-defining category

Key distinction: HER2-positive vs HER2-enriched

These terms are related but not interchangeable:

HER2-positive is a clinical laboratory result, determined by HER2 immunohistochemistry and/or in-situ hybridization.
HER2-enriched is a gene-expression intrinsic subtype.

Similarly, triple-negative is based on ER, PR, and HER2 testing, while basal-like is a gene-expression subtype. Many, but not all, triple-negative cancers are basal-like.

Why subtyping matters

Subtype affects:

Expected growth rate and recurrence pattern
Likelihood of response to endocrine treatment
Eligibility for HER2-targeted therapies
Use of chemotherapy, immunotherapy, and targeted medicines
Prognosis, alongside stage, grade, lymph-node status, and genomic assays

The NCI overview of breast-cancer types identifies luminal A, luminal B, HER2-positive, and triple-negative disease as key clinically relevant molecular categories.

This is a shared conversation. Sign in to Orris to start your own chat.